Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index; none of the 101 sources its claims cite is checked for support yet.
Abstract
Chimeric antigen receptor (CAR) T cells offer a promising strategy for the treatment of autoimmune diseases. However, clinical translation is limited by the high cost, complexity, and poor scalability of current manufacturing, restricting broad patient access and persisting safety concerns including insertional mutagenesis risk from integrating vectors and uncontrolled long-term CAR T cell persistence. In-vitro -transcribed (IVT) mRNA enables transient, non-integrating CAR expression with improved safety and scalability, making it particularly suited for non-malignant indications where prolonged persistence may not be required. Here, we systematically compare two IVT mRNA delivery platforms, electroporation and lipid nanoparticles (LNPs), for transient CAR T cell engineering in primary human T cells using single-cell transcriptomics and functional cell assays. We show that electroporation yields higher transfection efficiency and more sustained CAR surface expression, whereas LNP delivery reduces stress- and senescence-related transcriptional signatures as well as exhaustion marker expression, while enhancing antigen-driven activation, chemotactic responses, and cytotoxic function. Our comparative analysis highlights that the mode of mRNA delivery is associated with distinct transcriptional signatures and functional properties of CAR T cells, providing a framework to guide future development of mRNA-based approaches. These insights support LNP-mediated delivery as a functionally favorable strategy for transient CAR T cell engineering in autoimmune disease and beyond.
Overview
CoChat Summary
TL;DR
In primary human T cells, LNP-mediated IVT mRNA delivery produced lower CAR expression than electroporation but preserved cytotoxicity, improved migration, and reduced exhaustion/stress signatures. Electroporation achieved higher transfection and CAR density but induced stress, DNA damage, senescence, and exhaustion-associated programs.
Key findings
- Electroporation achieved >95% CD19-CAR+ T cells at 24 h and ∼4 × 10⁴ CD19-CAR molecules per cell, whereas LNP delivery reached ∼65% and ∼3 × 10³ molecules per cell; both peaked at 24 h, with detectable CAR for 4 days (electroporation) versus 3 days (LNP).
- Despite lower CAR expression, LNP-transfected CAR T cells achieved comparable target-cell killing and trended toward enhanced per-cell cytotoxicity; they also showed lower TIM-3 and LAG-3 across CD3+, CD4+, and CD8+ subsets, while PD-1 was unaffected, and trended toward improved CCL21 migration.
- scRNA-seq of 10,883 high-quality transcriptomes identified an electroporation-specific CD4+ cluster (cluster 8; 4.48%–16.2% of electroporated CD19-CAR T cells) enriched for ER stress, unfolded protein response, and DNA damage genes including TRIB3, DDIT3, CCPG1, SESN2, DNAJB9, and ATF3; LNP-transfected cells primarily activated interferon-stimulated genes such as IFI44L, MX1, IFI6, DDX60, RSAD2, XAF1, IRF7, and USP18 without stress or apoptotic signatures.
- IVT mRNA multiplexing via electroporation yielded >85% CD19-CAR+ T cells at 8 h and >95% at 24 h; CD19-CAR + CCR7 co-transfection gave a median 78.20% CD19-CAR+ T cells, four-mRNA delivery gave ∼90% CD19-CAR+GFP+ cells at 8 h, and CCR7 mRNA rescued migratory and cytotoxic function in CCR7 knockout T cells.
Methods
- Primary human T cells from healthy donors were isolated from PBMCs, CD3+ enriched by MACS, and polyclonally activated with plate-bound anti-CD3/CD28 for 48 h; on day 3, IVT mRNA encoding CD19-CAR, CCR7, CXCR3, or GFP was delivered by electroporation (Lonza 4D-Nucleofector, program EO-115) or LNP (GenVoy-ILM T-cell kit with ApoE), with mock and untouched controls.
- Functional readouts included transwell migration toward CCL21, live-cell imaging cytotoxicity against NALM6 and Raji target cells, serial killing assays, flow cytometry for activation/exhaustion/cytokines, Luminex cytokine analysis, and targeted scRNA-seq at 24 h post-transfection using 10× Genomics 5′ v2 with hashtag demultiplexing, Seurat clustering, DESeq2 pseudobulk differential expression, and GO module scores.
- Statistical analyses used paired t tests, one-way ANOVA with Tukey’s post hoc test, Friedman test with Dunn’s multiple comparison, two-way repeated-measures ANOVA with Šidák’s multiple-comparison test, and Pearson/Spearman correlation, with n = 3–8 independent donors depending on the assay.
Limitations
- Stated in the paper: results were obtained from a single LNP formulation; differences across electroporation platforms may prevent complete generalization of electroporation-induced phenotypes; the study focused exclusively on ex vivo delivery; direct assessment of persistence and long-term function in advanced animal disease models is still needed; and inter-donor variability was noted in the magnitude of CCR7-mediated killing effects.
- Evident from the text: the work is an in vitro study using healthy-donor T cells with small donor numbers (n = 3–8 across assays), without autoimmune patient samples or in vivo disease models, so clinical translation to persistence, safety, and therapeutic efficacy remains untested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
0 Valid · 0 Not valid · 36 Not checked · 105 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 8 h post-transfection, approximately 90% of T cells co-expressed CD19-CAR and GFP (Figures 1K and 1L)”
§ Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation > Results > IVT mRNA multiplexing enables efficient multi-protein expression in CAR T cells
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the absence of CCL21, both migration and subsequent target-cell killing were minimal (Figure S2B)”
§ Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation > Results > CCR7 IVT mRNA co-delivery improves lymphatic tissue-associated chemotaxis and functionality of mRNA-engineered CD19-CAR T cells
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Flow cytometric analysis confirmed consistently high transfection efficiencies (>85% CD19-CAR+ T cells at 8 h, >95% at 24 h post-transfection) across tested mRNA concentrations (1–3 μg)”
§ Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation > Results > IVT mRNA multiplexing enables efficient multi-protein expression in CAR T cells
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No evidence of translational competition was observed (Figure 1K).”
§ Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation > Results > IVT mRNA multiplexing enables efficient multi-protein expression in CAR T cells
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with protein expression reaching up to approximately 5 × 104 CD19-CAR molecules per cell at 24 h (Figure 1C).”
§ Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation > Results > IVT mRNA multiplexing enables efficient multi-protein expression in CAR T cells
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
60 more claims
Create a free account to see all 141 claims and to verify the 101 references still open.
- It may state two separate claims as one. 65
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In complex workflows, LNP-mediated mRNA delivery may offer advantages over electroporation for CAR T cell engineering, and our study extends this to a serial multi-round delivery context where the cell yield advantage compounds across transfection rounds.86”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [86]
In the citing paper
“Donors were not age- or sex-matched across experiments, and the number of donors was selected based on conventions in the primary T cell delivery literature rather than a formal power calculation.24,86,90,93,102”
From Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles (2026) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation > Results > IVT mRNA multiplexing enables efficient multi-protein expression in CAR T cells
“and viability (∼70% viability at 24 h; Figure 1G). Co-transfection yielded a median expression of 78.20% CD19-CAR+ T cells (range 53.60%–87.60%; Figure 1F)”
§ Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation > Results > IVT mRNA multiplexing enables efficient multi-protein expression in CAR T cells
“(F) Viability of T cells following single and dual mRNA transfection, assessed by live/dead staining 8 h post-transfection. (G–I) Quantification of CD19-CAR-only versus CD19-CAR + CCR7 co-expression: CD19-CAR+ frequency (G)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation > Results > CCR7 IVT mRNA co-delivery improves lymphatic tissue-associated chemotaxis and functionality of mRNA-engineered CD19-CAR T cells
“NALM6 target T cells (CD19+ GFP+)”
§ Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation > Results > LNP-transfected CAR T cells demonstrate superior functional fitness despite lower CAR expression
“Both LNP-transfected and electroporated CD19-CAR T cells demonstrated comparable killing across both B cell lines”
Citations
Cites
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Homing and cellular traffic in lymph nodes
von Andrian, U. H., & Mempel, T. R. (2003) · Nature Reviews Immunology · doi:10.1038/nri1222 · Cited by 1,281
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., Aigner, M., Rothe, T., Minopoulou, I., Tur, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308917 · Cited by 1,095
Self-citationAnti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
Self-citationFalse discovery rates: a new deal
Stephens, M. (2016) · Biostatistics · doi:10.1093/biostatistics/kxw041 · Cited by 1,067
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Viral and nonviral delivery systems for gene delivery
Nayerossadat, N., Maedeh, T., & Ali, P. (2012) · Advanced Biomedical Research · doi:10.4103/2277-9175.98152 · Cited by 858
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637 · cited 1×
“75 This process is time-consuming, costly, and highly dependent on the specific electroporation hardware.”
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Cited by
Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles
Ramamurthy, A., Scimonelli, G., Murphy, W. L., & Saha, K. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.103081
CAR-based therapies in systemic autoimmunity: from deep immune depletion toward durable immune reset
Zhang, H., Wu, B., Wan, H., Wu, K.-L., Tao, S., Zhou, Z., & Peng, Z. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117461
Huang, C., Zhang, X. L., Teng, Y., Zhang, Z., Wang, B., Gu, P., Deng, X., Wang, D., Xiao, H., Zou, L., et al. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s628321
Sun, Y., Xu, C., Lu, C., Ouyang, M., Shen, N., Wang, Y., Li, X., & Han, Y. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08426-y
Ren, Y., Lin, H., & Wei, J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115511
Metadata
- Authors
- Picht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., Krönke, G., Pichon, C., Sander, L. E., Volk, H.-D., Gossen, M., Schmueck-Henneresse, M., & Drzeniek, N. M.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Humboldt-Universität zu Berlin (DE)
- German Rheumatism Research Centre (DE)
- Université d'Orléans (FR)
- Helmholtz-Zentrum Hereon (DE)
- Corresponding author
- Drzeniek, Norman M.
- ORCID
- Venue
- Molecular Therapy Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2026-06
- Volume
- 37
- Issue
- 2
- Pages
- 102929
- ISSN
- 2162-2531 (ISSN-L)
- PMC
- PMC13139981
- OpenAlex
- W7151581709
- Cited by
- 7
- References
- 78
- Citations by year
- 2026: 7
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Molecular Therapy — Nucleic Acids (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by)
- Funders
- Federal Ministry of Education and Research Bonn Office
- Horizon Europe (101156595)
- Berlin-Brandenburger Centrum für Regenerative Therapien
- Stiftung Charité
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- chimeric antigen receptor T cells, lipid nanoparticles, electroporation, in vitro transcribed mRNA, CAR-T cell exhaustion, cytotoxicity, CAR-T cell engineering, autoimmune disease, transfection efficiency, senescence, chemotaxis, single-cell transcriptomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation. https://app.cochat.ai/papers/10.1016/j.omtn.2026.102929
- The paper
- Picht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., Krönke, G., Pichon, C., Sander, L. E., Volk, H.-D., Gossen, M., Schmueck-Henneresse, M., & Drzeniek, N. M. (2026). Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation. Molecular Therapy Nucleic Acids. https://doi.org/10.1016/j.omtn.2026.102929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.